[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fa8LBownvtBQyvgP_UwZGba9BjDoR_AyijgvYtwwRkL0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":44,"rows":51},"Hull University Teaching Hospitals NHS Trust",[4],93,false,18,4,123080,3,73,[14,17,20,22,24,26,28,31],{"name":15,"count":16},"Cough",8,{"name":18,"count":19},"Heart Failure",5,{"name":21,"count":19},"Varicose Veins",{"name":23,"count":11},"Polycystic Ovary Syndrome",{"name":25,"count":11},"Intermittent Claudication",{"name":27,"count":11},"COPD",{"name":29,"count":30},"Wound Infection",2,{"name":32,"count":30},"Asthma",[34,39],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06876506","Identification of B Regulatory Cells by Flow Cytometry","2027-04-28","Allergen Specific Immunotherapy",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06884280","Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study","2027-10","Monofer",[45,46,47,48,49,50],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[52,79,97,121,160,191,209,227,245,263,281,305,331,349,374,399,417,442,467,485,503,528,546,572,590,612,639,664,691,709,733,758],{"intervention":43,"totalTrials":53,"cells":54},1,{"EARLY_PHASE1":55,"PHASE1":58,"PHASE2":60,"PHASE3":62,"PHASE4":75,"NA":77},{"trials":56,"activeCount":57},[],0,{"trials":59,"activeCount":57},[],{"trials":61,"activeCount":57},[],{"trials":63,"activeCount":53,"soonestReadout":42},[64],{"nctId":40,"briefTitle":41,"status":65,"phases":66,"primaryCompletion":42,"completion":42,"start":67,"enrollment":68,"conditions":69,"interventions":73},"RECRUITING",[48],"2025-11-13",30,[70,71,72],"Peritoneal Dialysis","Anaemia","Iron Deficiency, Anaemia",[43,74],"Ferrous Sulfate",{"trials":76,"activeCount":57},[],{"trials":78,"activeCount":57},[],{"intervention":74,"totalTrials":53,"cells":80},{"EARLY_PHASE1":81,"PHASE1":83,"PHASE2":85,"PHASE3":87,"PHASE4":93,"NA":95},{"trials":82,"activeCount":57},[],{"trials":84,"activeCount":57},[],{"trials":86,"activeCount":57},[],{"trials":88,"activeCount":53,"soonestReadout":42},[89],{"nctId":40,"briefTitle":41,"status":65,"phases":90,"primaryCompletion":42,"completion":42,"start":67,"enrollment":68,"conditions":91,"interventions":92},[48],[70,71,72],[43,74],{"trials":94,"activeCount":57},[],{"trials":96,"activeCount":57},[],{"intervention":38,"totalTrials":53,"cells":98},{"EARLY_PHASE1":99,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":109},{"trials":100,"activeCount":57},[],{"trials":102,"activeCount":57},[],{"trials":104,"activeCount":57},[],{"trials":106,"activeCount":57},[],{"trials":108,"activeCount":57},[],{"trials":110,"activeCount":53,"soonestReadout":37},[111],{"nctId":35,"briefTitle":36,"status":112,"phases":113,"primaryCompletion":37,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":120},"NOT_YET_RECRUITING",[],"2027-07-31","2026-02-01",80,[118,119],"Pollen Allergy","Venom Allergy",[38,38],{"intervention":122,"totalTrials":30,"cells":123},"Sodium Tetradecyl Sulphate",{"EARLY_PHASE1":124,"PHASE1":126,"PHASE2":128,"PHASE3":130,"PHASE4":132,"NA":158},{"trials":125,"activeCount":57},[],{"trials":127,"activeCount":57},[],{"trials":129,"activeCount":57},[],{"trials":131,"activeCount":57},[],{"trials":133,"activeCount":57},[134,145],{"nctId":135,"briefTitle":136,"status":137,"phases":138,"primaryCompletion":139,"completion":140,"start":141,"enrollment":57,"conditions":142,"interventions":144},"NCT02010437","RCT Comparing Standard Cannula Delivered FS, UGFS and ClariVein® in the Management of SVI","WITHDRAWN",[49],"2015-01","2015-04","2014-01",[143],"Superficial Venous Insufficiency, Varicose Veins",[122],{"nctId":146,"briefTitle":147,"status":148,"phases":149,"primaryCompletion":150,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":155},"NCT02627846","Laser Ablation Versus Mechanochemical Ablation Trial","COMPLETED",[49],"2018-08-01","2023-09-04","2015-06-01",150,[21],[156,156,157,122],"Lidocaine with 1:200,000 epinephrine solution","Sodium Bicarbonate",{"trials":159,"activeCount":57},[],{"intervention":161,"totalTrials":53,"cells":162},"Co-amoxiclav",{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":169,"PHASE4":171,"NA":189},{"trials":164,"activeCount":57},[],{"trials":166,"activeCount":57},[],{"trials":168,"activeCount":57},[],{"trials":170,"activeCount":57},[],{"trials":172,"activeCount":57},[173],{"nctId":174,"briefTitle":175,"status":148,"phases":176,"primaryCompletion":177,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":183},"NCT02018094","The Amputation Surgical Site Infection Trial (ASSIT)",[49],"2014-03-01","2017-01-02","2013-10-08",160,[29,182],"Amputation Wound",[161,184,185,186,187,188],"Iodine","Metronidazole","Chlorhexidine","Teicoplanin","Clindamycin",{"trials":190,"activeCount":57},[],{"intervention":184,"totalTrials":53,"cells":192},{"EARLY_PHASE1":193,"PHASE1":195,"PHASE2":197,"PHASE3":199,"PHASE4":201,"NA":207},{"trials":194,"activeCount":57},[],{"trials":196,"activeCount":57},[],{"trials":198,"activeCount":57},[],{"trials":200,"activeCount":57},[],{"trials":202,"activeCount":57},[203],{"nctId":174,"briefTitle":175,"status":148,"phases":204,"primaryCompletion":177,"completion":178,"start":179,"enrollment":180,"conditions":205,"interventions":206},[49],[29,182],[161,184,185,186,187,188],{"trials":208,"activeCount":57},[],{"intervention":185,"totalTrials":53,"cells":210},{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":217,"PHASE4":219,"NA":225},{"trials":212,"activeCount":57},[],{"trials":214,"activeCount":57},[],{"trials":216,"activeCount":57},[],{"trials":218,"activeCount":57},[],{"trials":220,"activeCount":57},[221],{"nctId":174,"briefTitle":175,"status":148,"phases":222,"primaryCompletion":177,"completion":178,"start":179,"enrollment":180,"conditions":223,"interventions":224},[49],[29,182],[161,184,185,186,187,188],{"trials":226,"activeCount":57},[],{"intervention":186,"totalTrials":53,"cells":228},{"EARLY_PHASE1":229,"PHASE1":231,"PHASE2":233,"PHASE3":235,"PHASE4":237,"NA":243},{"trials":230,"activeCount":57},[],{"trials":232,"activeCount":57},[],{"trials":234,"activeCount":57},[],{"trials":236,"activeCount":57},[],{"trials":238,"activeCount":57},[239],{"nctId":174,"briefTitle":175,"status":148,"phases":240,"primaryCompletion":177,"completion":178,"start":179,"enrollment":180,"conditions":241,"interventions":242},[49],[29,182],[161,184,185,186,187,188],{"trials":244,"activeCount":57},[],{"intervention":187,"totalTrials":53,"cells":246},{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":253,"PHASE4":255,"NA":261},{"trials":248,"activeCount":57},[],{"trials":250,"activeCount":57},[],{"trials":252,"activeCount":57},[],{"trials":254,"activeCount":57},[],{"trials":256,"activeCount":57},[257],{"nctId":174,"briefTitle":175,"status":148,"phases":258,"primaryCompletion":177,"completion":178,"start":179,"enrollment":180,"conditions":259,"interventions":260},[49],[29,182],[161,184,185,186,187,188],{"trials":262,"activeCount":57},[],{"intervention":188,"totalTrials":53,"cells":264},{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":273,"NA":279},{"trials":266,"activeCount":57},[],{"trials":268,"activeCount":57},[],{"trials":270,"activeCount":57},[],{"trials":272,"activeCount":57},[],{"trials":274,"activeCount":57},[275],{"nctId":174,"briefTitle":175,"status":148,"phases":276,"primaryCompletion":177,"completion":178,"start":179,"enrollment":180,"conditions":277,"interventions":278},[49],[29,182],[161,184,185,186,187,188],{"trials":280,"activeCount":57},[],{"intervention":282,"totalTrials":53,"cells":283},"tredaptive",{"EARLY_PHASE1":284,"PHASE1":286,"PHASE2":288,"PHASE3":290,"PHASE4":292,"NA":303},{"trials":285,"activeCount":57},[],{"trials":287,"activeCount":57},[],{"trials":289,"activeCount":57},[],{"trials":291,"activeCount":57},[],{"trials":293,"activeCount":57},[294],{"nctId":295,"briefTitle":296,"status":148,"phases":297,"primaryCompletion":298,"completion":298,"start":299,"enrollment":300,"conditions":301,"interventions":302},"NCT01118598","Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome",[49],"2012-05","2010-06",34,[23],[282],{"trials":304,"activeCount":57},[],{"intervention":306,"totalTrials":53,"cells":307},"Montelukast",{"EARLY_PHASE1":308,"PHASE1":310,"PHASE2":312,"PHASE3":314,"PHASE4":316,"NA":329},{"trials":309,"activeCount":57},[],{"trials":311,"activeCount":57},[],{"trials":313,"activeCount":57},[],{"trials":315,"activeCount":57},[],{"trials":317,"activeCount":57},[318],{"nctId":319,"briefTitle":320,"status":148,"phases":321,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":327},"NCT02479074","The Utility of feNO in the Differential Diagnosis of Chronic Cough",[49],"2017-02-10","2017-03-09","2016-01",49,[15],[306,328,306],"Prednisolon, Montelukast",{"trials":330,"activeCount":57},[],{"intervention":328,"totalTrials":53,"cells":332},{"EARLY_PHASE1":333,"PHASE1":335,"PHASE2":337,"PHASE3":339,"PHASE4":341,"NA":347},{"trials":334,"activeCount":57},[],{"trials":336,"activeCount":57},[],{"trials":338,"activeCount":57},[],{"trials":340,"activeCount":57},[],{"trials":342,"activeCount":57},[343],{"nctId":319,"briefTitle":320,"status":148,"phases":344,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":345,"interventions":346},[49],[15],[306,328,306],{"trials":348,"activeCount":57},[],{"intervention":350,"totalTrials":53,"cells":351},"Erdosteine",{"EARLY_PHASE1":352,"PHASE1":354,"PHASE2":356,"PHASE3":358,"PHASE4":360,"NA":372},{"trials":353,"activeCount":57},[],{"trials":355,"activeCount":57},[],{"trials":357,"activeCount":57},[],{"trials":359,"activeCount":57},[],{"trials":361,"activeCount":57},[362],{"nctId":363,"briefTitle":364,"status":137,"phases":365,"primaryCompletion":366,"completion":367,"start":368,"enrollment":57,"conditions":369,"interventions":371},"NCT01176318","Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Erdosteine for Treatment of Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)",[49],"2011-10-12","2012-01-13","2010-08-10",[370],"Chronic Obstructive Pulmonary Disease",[350],{"trials":373,"activeCount":57},[],{"intervention":375,"totalTrials":53,"cells":376},"budesonide \u002F formoterol",{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":383,"PHASE4":385,"NA":397},{"trials":378,"activeCount":57},[],{"trials":380,"activeCount":57},[],{"trials":382,"activeCount":57},[],{"trials":384,"activeCount":57},[],{"trials":386,"activeCount":57},[387],{"nctId":388,"briefTitle":389,"status":148,"phases":390,"primaryCompletion":391,"completion":391,"start":392,"enrollment":393,"conditions":394,"interventions":395},"NCT01186653","Effect on Adrenal Function of Budesonide Versus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)",[49],"2010-05","2007-10",22,[370],[375,396],"fluticasone\u002Fsalmeterol",{"trials":398,"activeCount":57},[],{"intervention":396,"totalTrials":53,"cells":400},{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":407,"PHASE4":409,"NA":415},{"trials":402,"activeCount":57},[],{"trials":404,"activeCount":57},[],{"trials":406,"activeCount":57},[],{"trials":408,"activeCount":57},[],{"trials":410,"activeCount":57},[411],{"nctId":388,"briefTitle":389,"status":148,"phases":412,"primaryCompletion":391,"completion":391,"start":392,"enrollment":393,"conditions":413,"interventions":414},[49],[370],[375,396],{"trials":416,"activeCount":57},[],{"intervention":418,"totalTrials":53,"cells":419},"Ramipril",{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":426,"PHASE4":428,"NA":440},{"trials":421,"activeCount":57},[],{"trials":423,"activeCount":57},[],{"trials":425,"activeCount":57},[],{"trials":427,"activeCount":57},[],{"trials":429,"activeCount":57},[430],{"nctId":431,"briefTitle":432,"status":148,"phases":433,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":437,"interventions":439},"NCT01037530","Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants",[49],"2012-12","2010-12",33,[438],"Intermittent Claudicants",[418],{"trials":441,"activeCount":57},[],{"intervention":443,"totalTrials":53,"cells":444},"Ticagrelor",{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":449,"PHASE3":451,"PHASE4":453,"NA":465},{"trials":446,"activeCount":57},[],{"trials":448,"activeCount":57},[],{"trials":450,"activeCount":57},[],{"trials":452,"activeCount":57},[],{"trials":454,"activeCount":57},[455],{"nctId":456,"briefTitle":457,"status":148,"phases":458,"primaryCompletion":459,"completion":459,"start":460,"enrollment":461,"conditions":462,"interventions":464},"NCT02169596","Is Efficacy of PLAtelet Aggregation Inhibition by Ticagrelor Mediated P2Y12 Blockade Dependent Upon Endogenous Endothelial Nitric OXide?",[49],"2016-07","2015-06",74,[463],"Acute Coronary Syndome",[443],{"trials":466,"activeCount":57},[],{"intervention":156,"totalTrials":53,"cells":468},{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":475,"PHASE4":477,"NA":483},{"trials":470,"activeCount":57},[],{"trials":472,"activeCount":57},[],{"trials":474,"activeCount":57},[],{"trials":476,"activeCount":57},[],{"trials":478,"activeCount":57},[479],{"nctId":146,"briefTitle":147,"status":148,"phases":480,"primaryCompletion":150,"completion":151,"start":152,"enrollment":153,"conditions":481,"interventions":482},[49],[21],[156,156,157,122],{"trials":484,"activeCount":57},[],{"intervention":157,"totalTrials":53,"cells":486},{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":491,"PHASE3":493,"PHASE4":495,"NA":501},{"trials":488,"activeCount":57},[],{"trials":490,"activeCount":57},[],{"trials":492,"activeCount":57},[],{"trials":494,"activeCount":57},[],{"trials":496,"activeCount":57},[497],{"nctId":146,"briefTitle":147,"status":148,"phases":498,"primaryCompletion":150,"completion":151,"start":152,"enrollment":153,"conditions":499,"interventions":500},[49],[21],[156,156,157,122],{"trials":502,"activeCount":57},[],{"intervention":504,"totalTrials":53,"cells":505},"Empagliflozin",{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":510,"PHASE3":512,"PHASE4":524,"NA":526},{"trials":507,"activeCount":57},[],{"trials":509,"activeCount":57},[],{"trials":511,"activeCount":57},[],{"trials":513,"activeCount":57},[514],{"nctId":515,"briefTitle":516,"status":148,"phases":517,"primaryCompletion":518,"completion":518,"start":519,"enrollment":520,"conditions":521,"interventions":522},"NCT03008551","Empagliflozin vs Metformin in PCOS",[47,48],"2018-04-02","2017-08-18",40,[23],[504,523],"Metformin",{"trials":525,"activeCount":57},[],{"trials":527,"activeCount":57},[],{"intervention":523,"totalTrials":53,"cells":529},{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":542,"NA":544},{"trials":531,"activeCount":57},[],{"trials":533,"activeCount":57},[],{"trials":535,"activeCount":57},[],{"trials":537,"activeCount":57},[538],{"nctId":515,"briefTitle":516,"status":148,"phases":539,"primaryCompletion":518,"completion":518,"start":519,"enrollment":520,"conditions":540,"interventions":541},[47,48],[23],[504,523],{"trials":543,"activeCount":57},[],{"trials":545,"activeCount":57},[],{"intervention":547,"totalTrials":53,"cells":548},"Omeprazole",{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":555,"PHASE4":568,"NA":570},{"trials":550,"activeCount":57},[],{"trials":552,"activeCount":57},[],{"trials":554,"activeCount":57},[],{"trials":556,"activeCount":57},[557],{"nctId":558,"briefTitle":559,"status":560,"phases":561,"primaryCompletion":562,"completion":563,"start":564,"enrollment":19,"conditions":565,"interventions":566},"NCT00668317","Bronchial Hyper-responsiveness in Reflux Cough","TERMINATED",[48],"2009-09","2010-01","2006-09",[15],[547,567],"Ranitidine",{"trials":569,"activeCount":57},[],{"trials":571,"activeCount":57},[],{"intervention":567,"totalTrials":53,"cells":573},{"EARLY_PHASE1":574,"PHASE1":576,"PHASE2":578,"PHASE3":580,"PHASE4":586,"NA":588},{"trials":575,"activeCount":57},[],{"trials":577,"activeCount":57},[],{"trials":579,"activeCount":57},[],{"trials":581,"activeCount":57},[582],{"nctId":558,"briefTitle":559,"status":560,"phases":583,"primaryCompletion":562,"completion":563,"start":564,"enrollment":19,"conditions":584,"interventions":585},[48],[15],[547,567],{"trials":587,"activeCount":57},[],{"trials":589,"activeCount":57},[],{"intervention":591,"totalTrials":53,"cells":592},"escitalopram",{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":599,"PHASE4":608,"NA":610},{"trials":594,"activeCount":57},[],{"trials":596,"activeCount":57},[],{"trials":598,"activeCount":57},[],{"trials":600,"activeCount":57},[601],{"nctId":602,"briefTitle":603,"status":137,"phases":604,"enrollment":57,"conditions":605,"interventions":607},"NCT01522092","Escitalopram in Anxiety Associated Chronic Obstructive Pulmonary Disease (COPD) Exacerbations",[48],[606,27],"Anxiety",[591],{"trials":609,"activeCount":57},[],{"trials":611,"activeCount":57},[],{"intervention":613,"totalTrials":53,"cells":614},"Hyperbaric Oxygen",{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":633,"PHASE4":635,"NA":637},{"trials":616,"activeCount":57},[],{"trials":618,"activeCount":57},[],{"trials":620,"activeCount":57},[621],{"nctId":622,"briefTitle":623,"status":148,"phases":624,"primaryCompletion":625,"completion":626,"start":627,"enrollment":628,"conditions":629,"interventions":632},"NCT00623142","The Protective Effects Of Treatment With Hyperbaric Oxygen Prior To Bypass Heart Surgery",[46,47],"2007-01","2008-01","2005-01",81,[630,631],"Myocardial Reperfusion Injury","Cytoprotection",[613],{"trials":634,"activeCount":57},[],{"trials":636,"activeCount":57},[],{"trials":638,"activeCount":57},[],{"intervention":640,"totalTrials":53,"cells":641},"fostair",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":658,"PHASE4":660,"NA":662},{"trials":643,"activeCount":57},[],{"trials":645,"activeCount":57},[],{"trials":647,"activeCount":57},[648],{"nctId":649,"briefTitle":650,"status":148,"phases":651,"primaryCompletion":140,"completion":652,"start":653,"enrollment":654,"conditions":655,"interventions":657},"NCT02048644","Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis",[47],"2015-05","2014-03",20,[656],"Idiopathic Pulmonary Fibrosis",[640],{"trials":659,"activeCount":57},[],{"trials":661,"activeCount":57},[],{"trials":663,"activeCount":57},[],{"intervention":665,"totalTrials":53,"cells":666},"dalteparin",{"EARLY_PHASE1":667,"PHASE1":669,"PHASE2":671,"PHASE3":685,"PHASE4":687,"NA":689},{"trials":668,"activeCount":57},[],{"trials":670,"activeCount":57},[],{"trials":672,"activeCount":57},[673],{"nctId":674,"briefTitle":675,"status":148,"phases":676,"completion":677,"start":678,"enrollment":679,"conditions":680,"interventions":683},"NCT00462852","Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",[47],"2011-11","2003-04",120,[681,682],"Pancreatic Cancer","Thromboembolism",[665,684],"gemcitabine hydrochloride",{"trials":686,"activeCount":57},[],{"trials":688,"activeCount":57},[],{"trials":690,"activeCount":57},[],{"intervention":684,"totalTrials":53,"cells":692},{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":697,"PHASE3":703,"PHASE4":705,"NA":707},{"trials":694,"activeCount":57},[],{"trials":696,"activeCount":57},[],{"trials":698,"activeCount":57},[699],{"nctId":674,"briefTitle":675,"status":148,"phases":700,"completion":677,"start":678,"enrollment":679,"conditions":701,"interventions":702},[47],[681,682],[665,684],{"trials":704,"activeCount":57},[],{"trials":706,"activeCount":57},[],{"trials":708,"activeCount":57},[],{"intervention":710,"totalTrials":53,"cells":711},"Ambroxol Hydrochloride",{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":727,"PHASE4":729,"NA":731},{"trials":713,"activeCount":57},[],{"trials":715,"activeCount":57},[],{"trials":717,"activeCount":57},[718],{"nctId":719,"briefTitle":720,"status":148,"phases":721,"primaryCompletion":722,"completion":722,"start":723,"enrollment":724,"conditions":725,"interventions":726},"NCT03415269","A Study of the Effect of 20 mg Ambroxol Hydrochloride on Acute Cough.",[47],"2018-04-19","2018-02-15",14,[15],[710],{"trials":728,"activeCount":57},[],{"trials":730,"activeCount":57},[],{"trials":732,"activeCount":57},[],{"intervention":734,"totalTrials":53,"cells":735},"Azithromycin 250Mg",{"EARLY_PHASE1":736,"PHASE1":738,"PHASE2":740,"PHASE3":752,"PHASE4":754,"NA":756},{"trials":737,"activeCount":57},[],{"trials":739,"activeCount":57},[],{"trials":741,"activeCount":57},[742],{"nctId":743,"briefTitle":744,"status":148,"phases":745,"primaryCompletion":746,"completion":746,"start":747,"enrollment":748,"conditions":749,"interventions":751},"NCT04020380","Azithromycin a Treatment for Pulmonary Sarcoidosis",[47],"2020-06-20","2019-09-06",21,[750],"Sarcoidosis, Pulmonary",[734],{"trials":753,"activeCount":57},[],{"trials":755,"activeCount":57},[],{"trials":757,"activeCount":57},[],{"intervention":759,"totalTrials":53,"cells":760},"oxygen",{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":776,"PHASE4":778,"NA":780},{"trials":762,"activeCount":57},[],{"trials":764,"activeCount":57},[],{"trials":766,"activeCount":57},[767],{"nctId":768,"briefTitle":769,"status":148,"phases":770,"primaryCompletion":771,"completion":771,"start":772,"enrollment":773,"conditions":774,"interventions":775},"NCT02949531","Use of Oxygen in Heart Failure With Preserved Ejection Fraction",[47],"2017-02-15","2016-11-03",50,[18],[759],{"trials":777,"activeCount":57},[],{"trials":779,"activeCount":57},[],{"trials":781,"activeCount":57},[]]